Bifogade filer
File
Prenumeration
Beskrivning
| Land | Finland |
|---|---|
| Lista | Small Cap Helsinki |
| Sektor | Hälsovård |
| Industri | Medicinteknik |
Nightingale Health Plc
Press release
28 February 2025 at 12:35 p.m. (EET)
Nightingale Health Plc ("Nightingale Health"), a pioneer in disease risk detection and preventative health, will publish its half-year report for July - December 2024 on Thursday 6 March 2025 at around 9 a.m. EET. The materials will be made available soon after publication at http://ir.nightingalehealth.com.
Nightingale Health will arrange a live webcast for investors and media in English on 6 March 2025 at 2 p.m. EET. You can watch the webcast online at:
nightingalehealth.events.inderes.com/2024-2025-h1-results.
A presentation will be held by CEO Teemu Suna and CFO Tuukka Paavola. A recording of the event will be available later the same day at http://ir.nightingalehealth.com.
For further information, please contact:
Teemu Suna, CEO
ir@nightingalehealth.com
About Nightingale Health
Nightingale Health has developed the world's most advanced health check. Our solution provides risk detection for multiple chronic diseases from a single blood sample. Nightingale Health Check can be scaled to entire populations and it can replace many of the current routine disease risk assessments and health screening programs for chronic diseases. Detecting disease risks comprehensively and efficiently allows effective targeting and tracking of health interventions, and better prevention of chronic diseases. Nightingale Health's mission is to build sustainable healthcare and reduce health inequalities. With every sample we help to create a healthier world.
Nightingale Health operates globally with a parent company in Finland and eight subsidiaries in countries such as Japan, the United States, Singapore, and the United Kingdom. Nightingale Health has customers in more than 34 countries in the healthcare and medical research sectors. The company's technology is being used in many of the world's leading health initiatives, such as the UK Biobank, and over 600 peer-reviewed publications validate the technology. The company's Series B shares are listed on the First North Growth Market Finland marketplace. Read more: https://nightingalehealth.com/